A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma

Anti-Cancer Drugs

Volumn 21, Issue 8, 2010, Pages 777-784

  Chen, Jen Shi ^a   Chao, Yee ^b   Bang, Yung Jue ^c   Roca, Enrique ^d   Chung, Hyun C ^e   Palazzo, Felipe ^f   Kim, Yeul H ^g   Myrand, Scott P ^h   Mullaney, Brian P ^h   Shen, Li J ⁱ   Linn, Carlos ^c,j  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c Intercontinental Region   (Taiwan)

^d Seoul National University Hospital   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Korea University College of Medicine   (South Korea)

^g HOSPITAL DE GASTROENTEROLOGÍA DR CARLOS BONORINO UDAONDO   (Argentina)

^h San Miguel de Tucuman   (Argentina)

ⁱ ELI LILLY AND COMPANY   (United States)

^j Eli Lilly   (China)

more..

Author keywords

advanced gastric carcinoma; cisplatin; MTHFR; pemetrexed; pharmacogenetics; phase I II clinical trials; unresectable

Indexed keywords

CISPLATIN; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ALLELE; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE CONTROL; DNA POLYMORPHISM; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; GENOTYPE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; STOMACH CARCINOMA; TREATMENT RESPONSE; WILD TYPE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PHARMACOGENETICS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955231880     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833cfbca     Document Type: Article

References (35)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24:2137-2150.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
3. Swan R, Miner TJ. Current role of surgical therapy in gastric cancer. World J Gastroenterol 2006; 12:372-379.
4. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003; 14 (Suppl 2):ii31-ii36.
5. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta- analysis based on aggregate data. J Clin Oncol 2006; 24:2903-2909.
6. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18:2648-2657.
7. Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004; 15:1585-1595.
8. Lee JJ, Kim SY, Chung HC, Lee KH, Song HS, Kang WK, et al. A multi- center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer. Cancer Chemother Pharmacol 2009; 63:1083-1090.
9. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994; 70:380-383.
10. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17:319-323.
11. Celio L, Sternberg CN, Labianca R, La Torre I, Amoroso V, Barone C, et al. Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Ann Oncol 2009; 20:1062-1067.
12. Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, et al. A randomised multicentre phase II trial of capecitabine versus S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 2008; 99:584-590.
13. Hanna NH. Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed. Clin Lung Cancer 2004; 5 (Suppl 2):S75-S79.
14. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-2644.
15. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-3551.
16. Bajetta E, Celio L, Buzzoni R, Ferrari L, Marchiano A, Martinetti A, et al. Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol 2003; 14:1543-1548.
17. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17:409-422.
18. Kim JH, Lee KW, Jung Y, Kim TY, Ham HS, Jong HS, et al. Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci 2005; 96:365-371.
19. Kim YH, Chung HC, Kang WK, Park SR, Kim CS, Kim TY, et al. Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. Cancer Chemother Pharmacol 2008; 62:263-270.
20. De Mattia E, Toffoli G. C677Tand A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer 2009; 45:1333-1351.
21. Thodtmann R, Depenbrock H, Dumez H, Blatter J, Johnson RD, van Oosterom A, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999; 17:3009-3016.
22. Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA 1998; 95:13217-13220.
23. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64:169-1 72.
24. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71:3813-3818.
25. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9:827-831.
26. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24:4991-4997.
27. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36-46.
28. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26:1435-1442.
29. Inoue S, Hashiguchi M, Chiyoda T, Sunami Y, Tanaka T, Mochizuki M. Pharmacogenetic study of methylenetetrahydrofolate reductase and thymidylate synthase in Japanese and assessment of ethnic and gender differences. Pharmacogenomics 2007; 8:41-47.
30. Mao R, Fan Y, Chen F, Sun D, Bai J, Fu S. Methylenetetrahydrofolate reductase gene polymorphisms in 13 Chinese ethnic populations. Cell Biochem Funct 2008; 26:352-358. (Pubitemid 351613177)
31. Boccia S, Hung R, Ricciardi G, Gianfagna F, Ebert MP, Fang JY, et al. Meta- and pooled analyses of the methylenetetrahydrofolate reductase C677 T and A1298C polymorphisms and gastric cancer risk: a huge-GSEC review. Am J Epidemiol 2008; 167:505-516.
32. Etienne MC, Formento JL, Chazal M, Francoual M, Magne N, Formento P, et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004; 14:785-792.
33. Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006; 24:1883-1891. (Pubitemid 46638987)
34. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 24:3789-3798.
35. Fisher MC, Cronstein BN. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol.2009; 36: 539-545